Harrow, Inc. · NASDAQ:HROW
Harrow — Investor Presentation (March 2024)
24 slides from Harrow's investor presentation, Mar 19, 2024
Slide 1: Harrow Investor Presentation March 2024
Ve HARROW s. Our purpos Investor Presentation | March 2024
Slide 2: Safe Harbor
ee Safe Harbor This presentation contains express “forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlyin
Slide 3: Harrow, a leading North American ophthalmic pharmaceutical company
Harrow, a leading North American ophthalmic pharmaceutical company, partners with eyecare professionals to help preserve vision for millions of patients annually >$180,000 {in Movsanes} {in Thovsanek} $28,119 Financial Positive operating cash $130,193 flow for Q4 2023 and all 8 of 2023 2 $88,595 3 $
Slide 4: Harrow's Ophthalmic Pharmaceutical Brands
— Harrow’s Ophthalmic Pharmaceutical Brands a ILEVRO. IOPIDINE 1% _IOPIDINE 0.5% y 7 racionidine hydroch nonlone acetonide THEEZO... vevye (eptercophtaic GEC oT, peace ‘a 7 ‘ lysate oem Suspension) 0.3% ‘Sterile ‘Stele | | Anyi | larex neat TobraDex:ST pine sO (tobramycin/dexamethasone stove aoe Max
Slide 5: Investment Highlights
— Investment Highlights Aggregate annual revenue potential of $500M* by 2027: 1. IHEEZO was launched in May of 2023, with growth continuing in 2024 2. VEVYE was launched in January 2024 and has category-leading potential 3. TRIESENCE expected to re-launch as early as 2024 New Product 4. Anterior Seg
Slide 6: Experienced and Dedicated Management Team
Experienced and Dedicated Management Team Yi Chief Executive Officer, Chairman of the Board, and Founder HARROW Andrew R. Boll Chief financial Officer, Founder ¢o John P. Saharek Chief Commercial Officer, President and CEO, impr Joined Harrow in 20 Dennis E. Saadeh Chief Scientific Officer Joined Ha
Slide 7: IHEEZO
— IHEEZO FDA-approved in September 2022 First approved ocular anesthetic in nearly 14 years Launched in May of 2023 Broad indication allows IHEEZO use in all settings of care Only J-coded (J2403) ophthalmic anesthetic in U.S. Only separately reimbursable ophthalmic anesthetic in US. Orange bookisted
Slide 8: IHEEZO Commercial Abstract
IHEEZO Commercial Abstract <0 (9 G@ én) 6960) HARROW Adam Robinson Vice President of Sales — IHEEZO © 23+ years of industry experience © 10+ years in Buy and Bill market Mack Jeffress National Sales Manager — institutional © 23+ years of industry experience © 9* yearsin ophthalmology Ryan Barnes Nat
Slide 9: What Eyecare Professionals Say About IHEEZO
What Eyecare Professionals Say About IHEEZO “Initially, Iwas skeptical about a different ‘lidocaine- like gel.’ However, with IHEEZO, patients no longer complain about BSS irritation, reporting less discomfort during limbal relaxing incisions. In addition, IHEEZO's sustained anesthetic effect greatl
Slide 10: VEVYE
— VEVYE o The first and only water-free cyclosporine (0.1%) to treat the signs and symptoms of dry eye disease o Water-free products are growing the Rx DED unit market, increasing new Rx volume by over 38% year-over-year (Sept. '23 to Jan. '24 versus the prior 5-month period) o Orange book-listed pa
Slide 11: VEVYE Commercial Abstract
VEVYE Commercial Abstract Maria Lloyd National Sales Director, Dry Eye © 20+ Years in Dry Eye ©. Dry Eye Launch Experience (Restasis) Nhi Or Head of Comme; © 20* years in Industry © Significant Launch Experience to © Cindi White Vice President eting © 20+ Years in industry 1 9. 15+ Years in Dry Eye
Slide 12: What Eyecare Professionals Say About VEVYE
— What Eyecare Professionals Say About VEVYE ‘Wow, that feels great. | wouldn’t even know it's a medication,’ was the comment I heard from my 88-year-old patient when she tried VEVYE in my office. She had been on myriad of dry eye disease medications and treatments. She couldn't tolerate preservativ
Slide 13: What Eyecare Professionals Say About VEVYE
What Eyecare Professionals Say About VEVYE “Integrity in my clinic means everything to me. VEVYE has single handedly changed my prescribing habits for my dry eye patients. In fact, the product is so quick to effect symptom relief and vision stabilization that | now use this product myself. I've negl
Slide 14: TRIESENCE
— TRIESENCE (triamcinolone acetonic injectable suspesion 40 mg/mL HARROW Preservative-free triamcinolone acetonide suspension Key on-label indications: Visualization During Vitrectomy (420,000 procedures per year) Posterior Uveitis (100,000 diagnoses per year) Five-year history of being on FDA's Dru
Slide 15: What Eyecare Professionals Say About TRIESENCE
What Eyecare Professionals Say About TRIESENCE “Many retinal specialists, including myselt, regard TRIESENCE as invaluable for vitrectomy procedures, and we are excited about it’s relurn to the morkel. Due to its FDA-approved status and preservalive-free formulation, TRIESENCE is the preferred choic
Slide 16: Anterior Segment Products
Anterior Segment Products Bruce Kent © 38+ years of industry experience ophthalmology Portfolio includes: + Steroids, NSAIDs, and Anti-inflammatories * an OTC lubricant + an Antihistamine + Antibiotics and an Antifungal + Medication to treat vernal keratoconjunctivitis, a rare disease + Anti-glaucom
Slide 17: What Eyecare Professionals Say About Anterior Segment Products
What Eyecare Professionals Say About Anterior Segment Products “ILEVRO is the only FDA- approved pro-drug utilized post-operatively in cataract surgery. With over 3 million cases per year, and my 50,000 personal surgical cases, ILEVRO is extremely valuable in controling pain and inflammation, starfi
Slide 18: ImprimisRx Compounded Products
ImprimisRx Compounded Products imprimis ident of Sales Revenues* years of industry experience (Dollars in thousands) © 30+ years in Ophthalmology Greg Anderson Fred Weiss Imp Quality © 39% years of industry experience America's leading provider of sterile ophthalmic compounded products to U.S. eyeca
Slide 19: What Eyecare Professionals Say About ImprimisRx
What Eyecare Professionals Say About ImprimisRx “In a world that should be patient-centered, Harrow does it as welll as anybody. From non-opioid needle-free sedation with the MKO Melt, to antibiotics and combinations that make every step of the journey easier, |am grateful Harrow puts patients first
Slide 20: Equity Ownership: MELT-300
ee Equity Ownership svesvevs, HARROW melt PHARMACEUTICALS® MELT-300 MELT-300 is the flagship product candidate of Melt Pharmaceuticals, a former subsidiary of Harrow. MELT-300 is a non-IlV and non-opioid sublingual sedation medicine for short-duration medical procedures. MELT-300 is patented in the
Slide 21: Harrow's Commitment to Missions Around the World
ee Harrow’s Commitment to Missions Around the World Seeing Again Guatemala Mission Trip to Guatemala Benevolent Missions Intl (Belize) Vision Outreach Intl (Amazon) April 2023 April 2023 June 2023 October 2023 SES = ee a. Harro onatio y 0 in 2024, 0 donations to patients ir 2 elp over ountries. We a
Slide 22: Inspired by Warren Buffett and Charlie Munger, building Harrow for the long term
Inspired by the legendary American investors Warren Buffett and the late Charlie Munger, we are building Harrow for the long term. The kind of value we are trying to create doesn't happen in a quarter or two; it takes time. But together, the Harrow Family - our entrepreneurial employees and loyal st
Slide 23: References
ee References Slide 3 refers to “Adjusted EBITDA,” which the Company defines as net loss, excluding the effects of stock-based compensation and expenses, interest, taxes, depreciation, amortization, investment (income) loss, net, and, if any and when specified, other non-recurring income or expense
Slide 24: Harrow Contact
(» HARROW 102 Woodmont Blvd., Suite 610 Nashville, Tennessee 37205 www.Harrow.com Jamie Webb Director of Communications and Investor Relations i b@harrowinc.com Direct: 615-733-4737 Ys a J y 4 a A DD la Your patients. Our purpose. J Tad tf.